Key Points Merck is seeking ways to prepare for a significant upcoming patent cliff.The company has just announced another ...

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

The move bolsters Merck’s lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...

New Merck R&D chief Roger Perlmutter already has shaken up the drug maker's labs and plans more changes, including reducing the number of research projects in which the company invests.